GNRH1 and obesity due to melanocortin 4 receptor deficiency: As obesity and overweight have been demonstrated to be independently associated with a higher risk of cardiotoxicity derived from anthracycline treatment (pooled odds ratio 1.38 (95% CI, 1.06 to 1.80)), patients administered with GnRH analogues should be closely monitored for prevention and prompt management of weight gain.